Open AccessQuality of Life in Hormone Receptor–Positive HER‐2 + Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib
Author(s) -
Sherrill Beth,
Amonkar Mayur M.,
Sherif Bintu,
Maltzman Julie,
O'Rourke Lisa,
Johnston Stephen
Publication year - 2010
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2010-0012
Subject(s) - medicine , letrozole , lapatinib , metastatic breast cancer , quality of life (healthcare) , oncology , breast cancer , clinical endpoint , regimen , population , placebo , progression free survival , cancer , clinical trial , chemotherapy , trastuzumab , tamoxifen , pathology , alternative medicine , nursing , environmental health
Background. A phase III trial compared lapatinib plus letrozole (L + Let) with letrozole plus placebo (Let) as first‐line therapy for hormone receptor (HR) + metastatic breast cancer (MBC) patients. The primary endpoint of progression‐free survival (PFS) in patients whose tumors were human epidermal growth factor receptor (HER)‐2 + was significantly longer for L + Let than for Let (8.2 months versus 3 months; p = .019). This analysis focuses on quality of life (QOL) in the HER‐2 + population. Methods. QOL was assessed at screening, every 12 weeks, and at withdrawal using the Functional Assessment of Cancer Therapy–Breast (FACT–B). Changes from baseline were analyzed and the proportions of patients achieving minimally important differences in QOL scores were compared. Additional exploratory analyses evaluated how QOL changes reflected tumor progression status. Results. Among the 1,286 patients randomized, 219 had HER‐2 + tumors. Baseline QOL scores were comparable in the two arms. Mean changes in QOL scores were generally stable over time for patients who stayed on study. The average change from baseline on the FACT‐B total score in both arms was positive at all scheduled visits through week 48. There was no significant difference between the two treatment arms in the percentage of QOL responders. Conclusion. The addition of lapatinib to letrozole led to a significantly longer PFS interval while maintaining QOL during treatment, when compared with letrozole alone, thus confirming the clinical benefit of the combination therapy in the HR + HER‐2 + MBC patient population. This all oral regimen provides an effective option in this patient population, delaying the need for chemotherapy and its accompanying side effects.